Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026

Morgan Stanley maintained an Overweight EVMN analyst rating on Evommune, Inc. on February 18, 2026, while raising its price target to $54 from $36. This action came in a note flagged by TheFly and represents a stronger valuation view without changing the firm’s core recommendation. Investors should note the firm kept the rating but widened upside expectations via the new price target.